Curis (NASDAQ:CRIS) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Curis (NASDAQ:CRIS) to a strong sell rating in a research report released on Saturday.

CRIS has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Friday, July 17th. Zacks Research upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $43.00 price target (up from $17.00) on shares of Curis in a report on Friday, July 24th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $43.00.

Curis Price Performance

Shares of CRIS opened at $4.02 on Friday. Curis has a 12 month low of $3.61 and a 12 month high of $39.00. The stock’s 50-day moving average is $6.61 and its two-hundred day moving average is $12.32. The stock has a market cap of $7.84 million, a PE ratio of -0.17 and a beta of 3.13.

Curis (NASDAQ:CRIS) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47). On average, research analysts anticipate that Curis will post -33.29 earnings per share for the current year.

Institutional Investors Weigh In On Curis

A number of hedge funds have recently bought and sold shares of the business. Maverick Capital Ltd. grew its position in shares of Curis by 7.8% during the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after buying an additional 49,554 shares in the last quarter. Squarepoint Ops LLC raised its holdings in Curis by 17.9% in the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 8,973 shares in the last quarter. Armistice Capital LLC raised its holdings in Curis by 8.7% in the third quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after acquiring an additional 78,265 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Curis by 2,883,237.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after acquiring an additional 230,659 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Curis by 37.3% during the 4th quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after acquiring an additional 65,404 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.